Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients

Neurotechnology company Cognito Therapeutics announced a partnership with Aetion to develop a validated predictive model that will help identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.

The artificial intelligence model, built on roughly 5 million commercial and Medicare claims, will enable population-level risk and cost assessments for payers and integrated health systems, clinical study population, enrichment and, once it becomes available, will support deployment of Cognito's intervention to AD patients with the highest risk for rapid disease progression.

“Aetion is a leader in turning real-world data into [real-world evidence] to inform critical decision-making across product development, reimbursement and commercialization,” Brent Vaughan, CEO of Cognito Therapeutics, said a press release. “Our partnership with Aetion to develop an innovative model will accelerate our late-stage clinical programs and bring our therapy to the millions of patients living with [mild cognitive impairment] and Alzheimer’s disease, where safer options are still needed.”